A real-life cost-effectiveness evaluation of budesonide/formoterol maintenance and reliever therapy in asthma

Respiratory Medicine
B StällbergSHARE trial group

Abstract

To evaluate direct asthma-related costs in Swedish primary care in a real-life setting. 12-month open-label study. Swedish primary care in a real-life setting. 1776 patients with persistent asthma. Patients with persistent asthma were randomised to one of three treatments: a free adjustable combination of budesonide (100-400 microg/inhalation) and formoterol (4.5 or 9 microg/inhalation) via separate inhalers plus terbutaline as needed; budesonide/formoterol (160/4.5 microg or 80/4.5 microg, two inhalations twice daily) plus terbutaline as needed; budesonide/formoterol (160/4.5 microg or 80/4.5 microg, one inhalation twice daily or two inhalations once daily), for maintenance plus additional inhalations as needed. Doses depended on previous inhaled corticosteroid dose. Patients attended the clinic at 0, 1.5, and 12 months. Telephone interviews were conducted at 4, 6, 8, and 10 months. The primary endpoint was direct asthma-related healthcare costs. Statistically significant reductions in annual direct costs per patient were observed with budesonide/formoterol maintenance and reliever therapy compared with the free adjustable combination of budesonide and formoterol (-13%, P<0.001) and fixed-dose budesonide/formoterol plus terbut...Continue Reading

References

Nov 26, 1999·The European Respiratory Journal·E F JuniperD R King
Jun 11, 2004·Journal of Evaluation in Clinical Practice·Mike PearsonSarah Simnett
Jul 22, 2004·JAMA : the Journal of the American Medical Association·Don D SinS F Paul Man
Oct 27, 2004·American Journal of Respiratory and Critical Care Medicine·Paul M O'ByrneEric D Bateman
Mar 2, 2005·International Journal of Technology Assessment in Health Care·Cynthia P IglesiasUNKNOWN NEVALAT Project Group
Nov 3, 2005·The European Respiratory Journal·C VogelmeierD Price
Mar 17, 2007·International Journal of Clinical Practice·P KunaR Buhl

❮ Previous
Next ❯

Citations

Sep 22, 2009·Advances in Therapy·Lucas M A GoossensMaureen P M H Rutten-van Mölken
May 8, 2015·Lung India : Official Organ of Indian Chest Society·Ritesh AgarwalSubhash Varma
Apr 14, 2016·Expert Opinion on Pharmacotherapy·Ole D Wolthers
Mar 2, 2013·The Cochrane Database of Systematic Reviews·Bhupendrasinh F ChauhanFrancine M Ducharme
Sep 8, 2018·JAMA : the Journal of the American Medical Association·Diana M Sobieraj, William L Baker
Jan 23, 2009·The Cochrane Database of Systematic Reviews·Christopher J Cates, Toby J Lasserson
Jun 6, 2018·PharmacoEconomics·Carlos E Rodriguez-MartinezJose A Castro-Rodriguez
Jan 11, 2020·The European Respiratory Journal·Richard BeasleyIan D Pavord
Sep 8, 2018·JAMA : the Journal of the American Medical Association·Yang XiaHuahao Shen
Mar 13, 2020·International Journal of Chronic Obstructive Pulmonary Disease·Shiyuan ZhangAfisi S Ismaila
Dec 31, 2019·BMC Pulmonary Medicine·Richard BeasleyMark Weatherall
Dec 17, 2021·The Journal of Asthma : Official Journal of the Association for the Care of Asthma·Jefferson Antonio Buendía, Diana Guerrero Patiño

❮ Previous
Next ❯

Related Concepts

Related Feeds

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.